{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T04:38:30Z","timestamp":1768192710835,"version":"3.49.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Charles University Research Projects","award":["UNCE 204010 and PRVOUK P35"],"award-info":[{"award-number":["UNCE 204010 and PRVOUK P35"]}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["16-30345A"],"award-info":[{"award-number":["16-30345A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11906-016-0690-1","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T03:39:05Z","timestamp":1477539545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Should All Patients with Resistant Hypertension Receive Spironolactone?"],"prefix":"10.1007","volume":"18","author":[{"given":"J\u00e1n","family":"Rosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Zelinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ond\u0159ej","family":"Petr\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"\u0160trauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Holaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Ji\u0159\u00ed","family":"Widimsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"issue":"28","key":"690_CR1","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159\u2013219. doi:\n                      10.1093\/eurheartj\/eht151\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"5","key":"690_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A Sierra de la","year":"2011","unstructured":"de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898\u2013902. doi:\n                      10.1161\/HYPERTENSIONAHA.110.168948\n                      \n                    .","journal-title":"Hypertension"},{"issue":"13","key":"690_CR3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"issue":"3","key":"690_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/heartjnl-2011-300741","volume":"98","author":"RH Fagard","year":"2012","unstructured":"Fagard RH. Resistant hypertension. Heart. 2012;98(3):254\u201361. doi:\n                      10.1136\/heartjnl-2011-300741\n                      \n                    .","journal-title":"Heart"},{"issue":"4","key":"690_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/HCO.0b013e328353ad6e","volume":"27","author":"DR Roberie","year":"2012","unstructured":"Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol. 2012;27(4):386\u201391. doi:\n                      10.1097\/HCO.0b013e328353ad6e\n                      \n                    .","journal-title":"Curr Opin Cardiol"},{"issue":"6","key":"690_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jash.2016.03.186","volume":"10","author":"H Bhatt","year":"2016","unstructured":"Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens : JASH. 2016;10(6):493\u20139. doi:\n                      10.1016\/j.jash.2016.03.186\n                      \n                    .","journal-title":"J Am Soc Hypertens : JASH"},{"issue":"3","key":"690_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ajh\/hpu151","volume":"28","author":"D Achelrod","year":"2015","unstructured":"Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355\u201361. doi:\n                      10.1093\/ajh\/hpu151\n                      \n                    .","journal-title":"Am J Hypertens"},{"issue":"11","key":"690_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/jhh.2014.3","volume":"28","author":"J Rosa","year":"2014","unstructured":"Rosa J, Zelinka T, Petr\u00e1k O, \u0160trauch B, \u0160oml\u00f3ov\u00e1 Z, Indra T, et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens. 2014;28(11):684\u20138. doi:\n                      10.1038\/jhh.2014.3\n                      \n                    .","journal-title":"J Hum Hypertens"},{"key":"690_CR9","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 \u0160trauch B, Petr\u00e1k O, Zelinka T, Rosa J, \u0160oml\u00f3ov\u00e1 Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;ed2013:2455\u201361. This interesting study reveals the high number of non-adherent patients from the population of resistant hypertension, by use of quantitative plasma drug measurements.","DOI":"10.1097\/HJH.0b013e3283652c61"},{"issue":"8","key":"690_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11906-016-0669-y","volume":"18","author":"R Cifkova","year":"2016","unstructured":"Cifkova R, Fodor G, Wohlfahrt P. Changes in hypertension prevalence, awareness, treatment, and control in high-, middle-, and low-income countries: an update. Curr Hypertens Rep. 2016;18(8):62. doi:\n                      10.1007\/s11906-016-0669-y\n                      \n                    .","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"690_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/HYPERTENSIONAHA.116.06587","volume":"67","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertension. 2016;67(6):1085\u201392. doi:\n                      10.1161\/HYPERTENSIONAHA.116.06587\n                      \n                    .","journal-title":"Hypertension"},{"issue":"3","key":"690_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","volume":"63","author":"DA Calhoun","year":"2014","unstructured":"Calhoun DA, Booth 3rd JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451\u20138. doi:\n                      10.1161\/HYPERTENSIONAHA.113.02026\n                      \n                    .","journal-title":"Hypertension"},{"issue":"4","key":"690_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/jhh.2013.77","volume":"28","author":"A Oliveras","year":"2014","unstructured":"Oliveras A, de la Sierra A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens. 2014;28(4):213\u20137. doi:\n                      10.1038\/jhh.2013.77\n                      \n                    .","journal-title":"J Hum Hypertens"},{"key":"690_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","author":"E Berra","year":"2016","unstructured":"Berra E, Azizi M, Capron A, Hoieggen A, Rabbia F, Kjeldsen SE, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016. doi:\n                      10.1161\/HYPERTENSIONAHA.116.07464\n                      \n                    .","journal-title":"Hypertension"},{"issue":"1","key":"690_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/hr.2010.183","volume":"34","author":"J Ceral","year":"2011","unstructured":"Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res : Off J Jpn Soc Hypertens. 2011;34(1):87\u201390. doi:\n                      10.1038\/hr.2010.183\n                      \n                    .","journal-title":"Hypertens Res : Off J Jpn Soc Hypertens"},{"issue":"11","key":"690_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","volume":"100","author":"M Tomaszewski","year":"2014","unstructured":"Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis. Heart. 2014;100(11):855\u201361. doi:\n                      10.1136\/heartjnl-2013-305063\n                      \n                    .","journal-title":"Heart"},{"issue":"8","key":"690_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","volume":"63","author":"S Brinker","year":"2014","unstructured":"Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834\u20135. doi:\n                      10.1016\/j.jacc.2013.10.067\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"690_CR18","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1097\/HJH.0000000000000346","volume":"32","author":"O Chung","year":"2014","unstructured":"Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W, et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014;32(12):2411\u201321. doi:\n                      10.1097\/HJH.0000000000000346\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"12","key":"690_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.amjmed.2015.08.011","volume":"128","author":"U Hedegaard","year":"2015","unstructured":"Hedegaard U, Kjeldsen LJ, Pottegard A, Henriksen JE, Lambrechtsen J, Hangaard J, et al. Improving medication adherence in patients with hypertension: a randomized trial. Am J Med. 2015;128(12):1351\u201361. doi:\n                      10.1016\/j.amjmed.2015.08.011\n                      \n                    .","journal-title":"Am J Med"},{"key":"690_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12516","author":"V Fontil","year":"2016","unstructured":"Fontil V, Bibbins-Domingo K, Nguyen OK, Guzman D, Goldman LE. Management of hypertension in primary care safety-net clinics in the united states: a comparison of community health centers and private Physicians\u2019 offices. Health Serv Res. 2016. doi:\n                      10.1111\/1475-6773.12516\n                      \n                    .","journal-title":"Health Serv Res"},{"issue":"8","key":"690_CR21","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/HJH.0000000000000988","volume":"34","author":"J Redon","year":"2016","unstructured":"Redon J, Mourad JJ, Schmieder RE, Volpe M, Weiss TW. Why in 2016 are patients with hypertension not 100% controlled? A call to action. J Hypertens. 2016;34(8):1480\u20138. doi:\n                      10.1097\/HJH.0000000000000988\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"4","key":"690_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","volume":"62","author":"BM Egan","year":"2013","unstructured":"Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691\u20137. doi:\n                      10.1161\/HYPERTENSIONAHA.113.01448\n                      \n                    .","journal-title":"Hypertension"},{"key":"690_CR23","doi-asserted-by":"publisher","unstructured":"\u2022 Petr\u00e1k O, Zelinka T, \u0160trauch B, Rosa J, \u0160oml\u00f3ov\u00e1 Z, Indra T, et al. Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens. 2016;30(1):35\u20139. doi:\n                      10.1038\/jhh.2015.24\n                      \n                    . Interesting analysis of different types of combination therapy in a large sample of patients with uncontrolled hypertension (what combination of drugs may even be used in general practice).","DOI":"10.1038\/jhh.2015.24"},{"issue":"4","key":"690_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJMcp041698","volume":"355","author":"M Moser","year":"2006","unstructured":"Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355(4):385\u201392. doi:\n                      10.1056\/NEJMcp041698\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"22","key":"690_CR25","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","volume":"52","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749\u201357. doi:\n                      10.1016\/j.jacc.2008.08.036\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"690_CR26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","volume":"65","author":"GC Roush","year":"2015","unstructured":"Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041\u20136. doi:\n                      10.1161\/HYPERTENSIONAHA.114.05021\n                      \n                    .","journal-title":"Hypertension"},{"key":"690_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpw030","author":"GC Roush","year":"2016","unstructured":"Roush GC, Sica DA. Diuretics for hypertension: a review and update. Am J Hypertens. 2016. doi:\n                      10.1093\/ajh\/hpw030\n                      \n                    .","journal-title":"Am J Hypertens"},{"issue":"5","key":"690_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11906-007-0066-7","volume":"9","author":"E Pimenta","year":"2007","unstructured":"Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007;9(5):353\u20139.","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"690_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"SW Tobe","year":"2011","unstructured":"Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098\u2013107. doi:\n                      10.1161\/CIRCULATIONAHA.110.964171\n                      \n                    .","journal-title":"Circulation"},{"issue":"7","key":"690_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129(7):661\u20136. doi:\n                      10.1016\/j.amjmed.2016.01.039\n                      \n                    .","journal-title":"Am J Med"},{"issue":"1","key":"690_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.116.07418","volume":"68","author":"A Lother","year":"2016","unstructured":"Lother A, Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension. 2016;68(1):6\u201310. doi:\n                      10.1161\/HYPERTENSIONAHA.116.07418\n                      \n                    .","journal-title":"Hypertension"},{"key":"690_CR32","doi-asserted-by":"publisher","unstructured":"\u2022 Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010(8):CD008169. doi:\n                      10.1002\/14651858.CD008169.pub2\n                      \n                    . Interesting meta-analysis of studies with spironolactone with the aim of determining the effect of spironolactone monotherapy on mortality and morbidity and to quantify the magnitude of blood pressure lowering effect.","DOI":"10.1002\/14651858.CD008169.pub2"},{"issue":"4","key":"690_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839\u201345. doi:\n                      10.1161\/01.HYP.0000259805.18468.8c\n                      \n                    .","journal-title":"Hypertension"},{"issue":"1","key":"690_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F Souza de","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55(1):147\u201352. doi:\n                      10.1161\/HYPERTENSIONAHA.109.140988\n                      \n                    .","journal-title":"Hypertension"},{"issue":"6","key":"690_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","volume":"4","author":"M Engbaek","year":"2010","unstructured":"Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens : JASH. 2010;4(6):290\u20134. doi:\n                      10.1016\/j.jash.2010.10.001\n                      \n                    .","journal-title":"J Am Soc Hypertens : JASH"},{"issue":"5","key":"690_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","volume":"55","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55(5):1137\u201342. doi:\n                      10.1161\/HYPERTENSIONAHA.109.141531\n                      \n                    .","journal-title":"Hypertension"},{"issue":"5","key":"690_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"N Khosla","year":"2009","unstructured":"Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30(5):418\u201324. doi:\n                      10.1159\/000237742\n                      \n                    .","journal-title":"Am J Nephrol"},{"issue":"4","key":"690_CR38","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25(4):891\u20134. doi:\n                      10.1097\/HJH.0b013e328014954d\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"12 Pt 1","key":"690_CR39","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","volume":"18","author":"A Mahmud","year":"2005","unstructured":"Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18(12 Pt 1):1631\u20135. doi:\n                      10.1016\/j.amjhyper.2005.06.010\n                      \n                    .","journal-title":"Am J Hypertens"},{"issue":"11 Pt 1","key":"690_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925\u201330.","journal-title":"Am J Hypertens"},{"issue":"4 Pt 1","key":"690_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15(4 Pt 1):333\u20139.","journal-title":"Am J Hypertens"},{"issue":"8","key":"690_CR42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jhh.2011.60","volume":"26","author":"R Pisoni","year":"2012","unstructured":"Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell\u2019Italia LJ, Cofield SS, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26(8):502\u20136. doi:\n                      10.1038\/jhh.2011.60\n                      \n                    .","journal-title":"J Hum Hypertens"},{"issue":"7","key":"690_CR43","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","volume":"19","author":"Y Sharabi","year":"2006","unstructured":"Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006;19(7):750\u20135. doi:\n                      10.1016\/j.amjhyper.2005.11.016\n                      \n                    .","journal-title":"Am J Hypertens"},{"issue":"5","key":"690_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1751-7176.2009.00110.x","volume":"11","author":"S Ubaid-Girioli","year":"2009","unstructured":"Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, et al. Aldosterone excess or escape: treating resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(5):245\u201352.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"690_CR45","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J V\u00e1clav\u00edk","year":"2011","unstructured":"V\u00e1clav\u00edk J, Sedl\u00e1k R, Plach\u00fd M, Navr\u00e1til K, Pl\u00e1\u0161ek J, Jarkovsk\u00fd J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069\u201375. doi:\n                      10.1161\/HYPERTENSIONAHA.111.169961\n                      \n                    .","journal-title":"Hypertension"},{"issue":"1","key":"690_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5507\/bp.2012.078","volume":"157","author":"J Vaclavik","year":"2013","unstructured":"Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia. 2013;157(1):50\u20135. doi:\n                      10.5507\/bp.2012.078\n                      \n                    .","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia"},{"key":"690_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpw105","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Calhoun DA. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am J Hypertens. 2016. doi:\n                      10.1093\/ajh\/hpw105\n                      \n                    .","journal-title":"Am J Hypertens"},{"issue":"8","key":"690_CR48","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","volume":"30","author":"G Bobrie","year":"2012","unstructured":"Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30(8):1656\u201364. doi:\n                      10.1097\/HJH.0b013e3283551e98\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"11","key":"690_CR49","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","volume":"28","author":"B Alvarez-Alvarez","year":"2010","unstructured":"Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28(11):2329\u201335. doi:\n                      10.1097\/HJH.0b013e32833d4c99\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"2","key":"690_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0300-8932(09)70158-7","volume":"62","author":"E Rodilla","year":"2009","unstructured":"Rodilla E, Costa JA, Perez-Lahiguera F, Baldo E, Gonzalez C, Pascual JM. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol. 2009;62(2):158\u201366.","journal-title":"Rev Esp Cardiol"},{"issue":"10","key":"690_CR51","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"CS Oxlund","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31(10):2094\u2013102. doi:\n                      10.1097\/HJH.0b013e3283638b1a\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"1","key":"690_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13410-012-0063-5","volume":"32","author":"SK Kota","year":"2012","unstructured":"Kota SK, Jammula S, Kota SK, Meher LK, Modi KD. Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension. Int J Diabet Dev Countries. 2012;32(1):33\u20136. doi:\n                      10.1007\/s13410-012-0063-5\n                      \n                    .","journal-title":"Int J Diabet Dev Countries"},{"issue":"8","key":"690_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/nep.12475","volume":"20","author":"U Verdalles","year":"2015","unstructured":"Verdalles U, Garcia de Vinuesa S, Goicoechea M, Macias N, Santos A, Perez de Jose A, et al. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy? Nephrology (Carlton). 2015;20(8):567\u201371. doi:\n                      10.1111\/nep.12475\n                      \n                    .","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"690_CR54","first-page":"75","volume":"22","author":"R Abolghasmi","year":"2011","unstructured":"Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl. 2011;22(1):75\u20138.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"9","key":"690_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jch.12374","volume":"16","author":"X Ni","year":"2014","unstructured":"Ni X, Zhang J, Zhang P, Wu F, Xia M, Ying G, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens (Greenwich). 2014;16(9):658\u201363. doi:\n                      10.1111\/jch.12374\n                      \n                    .","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"690_CR56","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015. doi:\n                      10.1016\/S0140-6736(15)00257-3\n                      \n                    . This randomized, double-blind crossover study confirmed the superiority of spironolactone in comparison to bisoprolol or doxazosin in resistant hypertension.","DOI":"10.1016\/S0140-6736(15)00257-3"},{"issue":"5","key":"690_CR57","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/HJH.0000000000000870","volume":"34","author":"L Ghazi","year":"2016","unstructured":"Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016;34(5):1005\u201310. doi:\n                      10.1097\/HJH.0000000000000870\n                      \n                    .","journal-title":"J Hypertens"},{"key":"690_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coph.2016.01.005","volume":"27","author":"MH Shahin","year":"2016","unstructured":"Shahin MH, Johnson JA. Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. Curr Opin Pharmacol. 2016;27:31\u20137. doi:\n                      10.1016\/j.coph.2016.01.005\n                      \n                    .","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"690_CR59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.semnephrol.2014.04.007","volume":"34","author":"DA Sica","year":"2014","unstructured":"Sica DA. Aldosterone and volume management in hypertensive heart disease. Semin Nephrol. 2014;34(3):323\u201332. doi:\n                      10.1016\/j.semnephrol.2014.04.007\n                      \n                    .","journal-title":"Semin Nephrol"},{"issue":"5","key":"690_CR60","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/HJH.0000000000000119","volume":"32","author":"T Wolak","year":"2014","unstructured":"Wolak T, Toledano R, Novack V, Sharon A, Shalev A, Wolak A. Doxazosin to treat hypertension: it\u2019s time to take it personally\u2014a retrospective analysis of 19\u200a495 patients. J Hypertens. 2014;32(5):1132\u20137. doi:\n                      10.1097\/HJH.0000000000000119\n                      \n                    .","journal-title":"J Hypertens"},{"key":"690_CR61","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376\u201385. doi:\n                      10.1093\/ajh\/hpv031\n                      \n                    . One of the most recent meta-analysis of randomized and non-randomized studies with aldosterone antagonist addition in resistant hypertension.","DOI":"10.1093\/ajh\/hpv031"},{"issue":"5","key":"690_CR62","first-page":"7270","volume":"8","author":"H Guo","year":"2015","unstructured":"Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp Med. 2015;8(5):7270\u20138.","journal-title":"Int J Clin Exp Med"},{"key":"690_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2016.02.016","author":"C Wang","year":"2016","unstructured":"Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016. doi:\n                      10.1016\/j.hlc.2016.02.016\n                      \n                    .","journal-title":"Heart Lung Circ"},{"issue":"9","key":"690_CR64","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30(9):534\u201342. doi:\n                      10.1038\/jhh.2015.119\n                      \n                    .","journal-title":"J Hum Hypertens"},{"issue":"5","key":"690_CR65","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. doi:\n                      10.1210\/jc.2015-4061\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"key":"690_CR66","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000464","author":"R Holaj","year":"2014","unstructured":"Holaj R, Rosa J, Zelinka T, Strauch B, Petrak O, Indra T, et al. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. J Hypertens. 2014. doi:\n                      10.1097\/HJH.0000000000000464\n                      \n                    .","journal-title":"J Hypertens"},{"key":"690_CR67","doi-asserted-by":"publisher","DOI":"10.1177\/1470320314549220","author":"T Indra","year":"2014","unstructured":"Indra T, Holaj R, Strauch B, Rosa J, Petrak O, Somloova Z, et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin-Angiotensin-Aldosterone Syst : JRAAS. 2014. doi:\n                      10.1177\/1470320314549220\n                      \n                    .","journal-title":"J Renin-Angiotensin-Aldosterone Syst : JRAAS"},{"issue":"6","key":"690_CR68","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1291\/hypres.25.837","volume":"25","author":"A Sato","year":"2002","unstructured":"Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res : Off J Jpn Soc Hypertens. 2002;25(6):837\u201342.","journal-title":"Hypertens Res : Off J Jpn Soc Hypertens"},{"issue":"13","key":"690_CR69","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2169\/internalmedicine.54.3427","volume":"54","author":"T Shibata","year":"2015","unstructured":"Shibata T, Tsutsumi J, Hasegawa J, Sato N, Murashima E, Mori C, et al. Effects of add-on therapy consisting of a selective mineralocorticoid receptor blocker on arterial stiffness in patients with uncontrolled hypertension. Intern Med. 2015;54(13):1583\u20139. doi:\n                      10.2169\/internalmedicine.54.3427\n                      \n                    .","journal-title":"Intern Med"},{"issue":"10","key":"690_CR70","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317. doi:\n                      10.1056\/NEJM199909023411001\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"1","key":"690_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"GC Roush","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens. 2016;34(1):11\u20139. doi:\n                      10.1097\/HJH.0000000000000762\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"6","key":"690_CR72","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension. 2008;51(6):1403\u201319. doi:\n                      10.1161\/HYPERTENSIONAHA.108.189141\n                      \n                    .","journal-title":"Hypertension"},{"key":"690_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12860","author":"K Eguchi","year":"2016","unstructured":"Eguchi K, Kabutoya T, Hoshide S, Ishikawa S, Kario K. Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension. J Clin Hypertens (Greenwich). 2016. doi:\n                      10.1111\/jch.12860\n                      \n                    .","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"690_CR74","unstructured":"Summary of product characteristics in Czech Republic\u2014Inspra. 2014; Available at: \n                      http:\/\/www.sukl.cz\/modules\/medication\/download.php?file=SPC73205.pdf&type=spc&as=inspra-25-mg-spc\n                      \n                    ."},{"key":"690_CR75","unstructured":"Electronic Medicine Compendium. Summary of product charachteristics\u2014Inspra. Available at: \n                      http:\/\/www.medicines.org.uk\/EMC\/medicine\/16746\/SPC\/Inspra+25mg+%26+50+mg+film-coated+tablets\/\n                      \n                    . 2015."},{"key":"690_CR76","unstructured":"Inspra Label\u2014gov.fda.accessdata.www. 2015; Available at: \n                      http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021437s006lbl.pdf\n                      \n                    ."},{"issue":"8","key":"690_CR77","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2174\/138920007782798135","volume":"8","author":"I Ragueneau-Majlessi","year":"2007","unstructured":"Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab. 2007;8(8):810\u20134.","journal-title":"Curr Drug Metab"},{"issue":"27","key":"690_CR78","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314. doi:\n                      10.1093\/eurheartj\/ehw132\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"5","key":"690_CR79","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.114.03246","volume":"63","author":"FE Fadl Elmula","year":"2014","unstructured":"Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63(5):991\u20139. doi:\n                      10.1161\/HYPERTENSIONAHA.114.03246\n                      \n                    .","journal-title":"Hypertension"},{"issue":"13","key":"690_CR80","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jacc.2015.01.037","volume":"65","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D\u2019Agostino R, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314\u201321. doi:\n                      10.1016\/j.jacc.2015.01.037\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"690_CR81","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/HYPERTENSIONAHA.115.05283","volume":"65","author":"S Desch","year":"2015","unstructured":"Desch S, Okon T, Heinemann D, Kulle K, Rohnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202\u20138. doi:\n                      10.1161\/HYPERTENSIONAHA.115.05283\n                      \n                    .","journal-title":"Hypertension"},{"issue":"5","key":"690_CR82","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/08037051.2015.1058595","volume":"24","author":"FE Fadl Elmula","year":"2015","unstructured":"Fadl Elmula FE, Jin Y, Yang WY, Thijs L, Lu YC, Larstorp AC, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24(5):263\u201374. doi:\n                      10.3109\/08037051.2015.1058595\n                      \n                    .","journal-title":"Blood Press"},{"issue":"3","key":"690_CR83","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/10641963.2015.1089881","volume":"38","author":"Y Yao","year":"2016","unstructured":"Yao Y, Zhang D, Qian J, Deng S, Huang Y, Huang J. The effect of renal denervation on resistant hypertension: meta-analysis of randomized controlled clinical trials. Clin Exp Hypertens. 2016;38(3):278\u201386. doi:\n                      10.3109\/10641963.2015.1089881\n                      \n                    .","journal-title":"Clin Exp Hypertens"},{"issue":"9981","key":"690_CR84","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","volume":"385","author":"M Azizi","year":"2015","unstructured":"Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957\u201365. doi:\n                      10.1016\/S0140-6736(14)61942-5\n                      \n                    .","journal-title":"Lancet"},{"issue":"9","key":"690_CR85","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/HJH.0000000000001025","volume":"34","author":"A Oliveras","year":"2016","unstructured":"Oliveras A, Armario P, Clara A, Sans-Atxer L, Vazquez S, Pascual J, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study\u2014a randomized controlled trial. J Hypertens. 2016;34(9):1863\u201371. doi:\n                      10.1097\/HJH.0000000000001025\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"12","key":"690_CR86","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1097\/HJH.0b013e3283652c61","volume":"31","author":"B \u0160trauch","year":"2013","unstructured":"\u0160trauch B, Petr\u00e1k O, Zelinka T, Rosa J, \u0160oml\u00f3\u00f3v\u00e1 Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455\u201361. doi:\n                      10.1097\/HJH.0b013e3283652c61\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"2","key":"690_CR87","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/HYPERTENSIONAHA.114.04019","volume":"65","author":"J Rosa","year":"2015","unstructured":"Rosa J, Widimsk\u00fd P, Tou\u0161ek P, Petr\u00e1k O, \u010curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65(2):407\u201313. doi:\n                      10.1161\/HYPERTENSIONAHA.114.04019\n                      \n                    .","journal-title":"Hypertension"},{"issue":"2","key":"690_CR88","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","volume":"67","author":"J Rosa","year":"2016","unstructured":"Rosa J, Widimsk\u00fd P, Waldauf P, Lambert L, Zelinka T, T\u00e1borsk\u00fd M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2016;67(2):397\u2013403. doi:\n                      10.1161\/HYPERTENSIONAHA.115.06526\n                      \n                    .","journal-title":"Hypertension"},{"issue":"3","key":"690_CR89","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.115.06486","volume":"67","author":"K Heusser","year":"2016","unstructured":"Heusser K, Tank J, Brinkmann J, Menne J, Kaufeld J, Linnenweber-Held S, et al. Acute response to unilateral unipolar electrical carotid sinus stimulation in patients with resistant arterial hypertension. Hypertension. 2016;67(3):585\u201391. doi:\n                      10.1161\/HYPERTENSIONAHA.115.06486\n                      \n                    .","journal-title":"Hypertension"},{"issue":"9978","key":"690_CR90","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0140-6736(14)62053-5","volume":"385","author":"MD Lobo","year":"2015","unstructured":"Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385(9978):1634\u201341. doi:\n                      10.1016\/S0140-6736(14)62053-5\n                      \n                    .","journal-title":"Lancet"},{"issue":"1","key":"690_CR91","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/HJH.0000000000000361","volume":"33","author":"M Wallbach","year":"2015","unstructured":"Wallbach M, Lehnig LY, Schroer C, Helms HJ, Luders S, Patschan D, et al. Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Hypertens. 2015;33(1):181\u20136. doi:\n                      10.1097\/HJH.0000000000000361\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"3","key":"690_CR92","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1016\/j.crvasa.2015.01.003","volume":"57","author":"J Filipovsk\u00fd","year":"2015","unstructured":"Filipovsk\u00fd J, Monhart V, Widimsk\u00fd Jr J. An update of the expert consensus statement of the Czech Hypertension Society on renal denervation in resistant hypertension. Cor Vasa. 2015;57(3):e187\u20139. doi:\n                      10.1016\/j.crvasa.2015.01.003\n                      \n                    .","journal-title":"Cor Vasa"},{"issue":"1","key":"690_CR93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/heartjnl-2014-307029","volume":"101","author":"MD Lobo","year":"2015","unstructured":"Lobo MD, de Belder MA, Cleveland T, Collier D, Dasgupta I, Deanfield J, et al. Joint UK societies\u2019 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101(1):10\u20136. doi:\n                      10.1136\/heartjnl-2014-307029\n                      \n                    .","journal-title":"Heart"},{"issue":"33","key":"690_CR94","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/eurheartj\/ehv192","volume":"36","author":"F Mahfoud","year":"2015","unstructured":"Mahfoud F, Bohm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219\u201327. doi:\n                      10.1093\/eurheartj\/ehv192\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"1","key":"690_CR95","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11906-015-0610-9","volume":"18","author":"A Persu","year":"2016","unstructured":"Persu A, Kjeldsen S, Staessen JA, Azizi M. Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep. 2016;18(1):6. doi:\n                      10.1007\/s11906-015-0610-9\n                      \n                    .","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"690_CR96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/HYPERTENSIONAHA.115.06616","volume":"67","author":"RM Carey","year":"2016","unstructured":"Carey RM. Resistant hypertension: mineralocorticoid receptor antagonist or renal denervation? Hypertension. 2016;67(2):278\u201380. doi:\n                      10.1161\/HYPERTENSIONAHA.115.06616\n                      \n                    .","journal-title":"Hypertension"},{"key":"690_CR97","doi-asserted-by":"publisher","unstructured":"\u2022 Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014;16(2):414. doi:\n                      10.1007\/s11906-013-0414-8\n                      \n                    . Interesting review of aldosterone receptor antagonists\u2019 safety profile.","DOI":"10.1007\/s11906-013-0414-8"},{"issue":"3-4","key":"690_CR98","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000369138","volume":"128","author":"S Gwoo","year":"2014","unstructured":"Gwoo S, Kim YN, Shin HS, Jung YS, Rim H. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease. Nephron Clin Pract. 2014;128(3-4):381\u20136. doi:\n                      10.1159\/000369138\n                      \n                    .","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"690_CR99","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","volume":"40","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40(2):304\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"690_CR100","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"690_CR101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31(1):3\u201315. doi:\n                      10.1097\/HJH.0b013e3283599b6a\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"5","key":"690_CR102","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy HK, Menard J, White WB, Young Jr WF, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980\u201390. doi:\n                      10.1097\/HJH.0b013e3283455ca5\n                      \n                    .","journal-title":"J Hypertens"},{"key":"690_CR103","doi-asserted-by":"publisher","first-page":"e4447","DOI":"10.1136\/bmj.e4447","volume":"345","author":"IS Mackenzie","year":"2012","unstructured":"Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ. 2012;345:e4447. doi:\n                      10.1136\/bmj.e4447\n                      \n                    .","journal-title":"BMJ"},{"issue":"14","key":"690_CR104","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321. doi:\n                      10.1056\/NEJMoa030207\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"1","key":"690_CR105","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. doi:\n                      10.1056\/NEJMoa1009492\n                      \n                    .","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-016-0690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-016-0690-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-016-0690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T22:13:09Z","timestamp":1581977589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-016-0690-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1007\/s11906-016-0690-1","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]},"assertion":[{"value":"27 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"81"}}